GA/18β as an immunomodulator treatment
SARS-CoV-2 infection
SARS-COV-2 INFECTION, INFLAMMATORY RESPONSE
The nebulization of the GA/18β drug for the treatment of SARS-CoV-2 infection resulted in the modulation of cytokines that play a role in the progression of the illness, acting as either pro-inflammatory or antiviral inducers. Previous studies have demonstrated that both GA and 18β have the potential to control cytokine induction in inflammatory processes (In addition to the modulation of interleukins, we observed alterations in the levels of SARS-CoV-2 antibodies due to the treatments. In COVID-19 patients, the lower dose of GA/18β increased IgM levels and maintained IgG levels with no significant fluctuations over time. This elevation in IgM levels might be connected to the aforementioned interleukin modulation, given that IgM is the initial immunoglobulin to emerge in the immune response, aiding in the clearance of pathogens during their early stages. This could potentially lead to a reduced inflammatory response in subsequent stages of COVID-19 progression (Discrepancies in IgG levels between the two GA/18β treatment doses were also observed. The higher dose exhibited a tendency to elevate IgG levels starting from day 11, in comparison to the lower dose. Although this pattern was not significant, it was similar to the reported by Li and Zhou (